ONCAlert | 2018 ASCO Annual Meeting

Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

Hope S. Rugo, MD
Published Online: 11:32 PM, Fri December 9, 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses what sets abemaciclib apart from other CDK 4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.